Sentences with phrase «lung cancer patients better»

Both of the researchers, who are in their early forties, said they were motivated by the need to give lung cancer patients better options.

Not exact matches

That's not just because of Opdivo's failure — last month, Keytruda was shown to be better than standard chemotherapy in untreated advanced lung cancer patients with high levels of the PD - L1 protein, both stopping cancer progression and extending patients» lives.

The company actually beat Wall Street profit estimates largely thanks to its superstar cancer immunotherapy drug Keytruda, which has been shown to best chemotherapy in helping lung cancer patients live longer and given Merck a leg up over rivals like Bristol - Myers Squibb's immune therapy Opdivo.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

For example, lung cancer patients who were injected with killed M. vaccae reported better quality of life and less nausea and pain.

Led by associate professor of pathology and Yale Cancer Center member Don Nguyen, PhD, the researchers analyzed RNA from patients with disease that was limited to the lungs as well as cancers that had spread.

These studies enrolled a total of 12,361 patients diagnosed with a variety of cancers, including lung, breast, skin, and prostate, as well as blood cancers such as leukemia, lymphoma, and myeloma.

Key findings in this study show that 5 - year survival for older lung cancer surgery patients is favorable; surgeons will be able to better individualize care for older lung cancer patients based on newly and uniquely linked data, and the prevalence of lung cancer is expected to increase as the population continues to age.

«Our findings suggest that this new drug combination would also help patients with this type of aggressive breast cancer as well as other cancers, such as lung, prostate and ovarian cancers,» Dr. Rassool says.

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option.

Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC).

Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient - matched tumor tissue DNA.

«Chemotherapy may be better for certain patients with advanced lung cancer.»

An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.

The same benefits of increased activity observed in lung cancer patients, especially improved symptoms and quality of life, appear to apply to lung cancer survivors as well.

Chronically - ill cancer patients have different exercise limitations than their healthy counterparts and other concurrent diseases and high symptom burden add challenges in how best to study and implement physical activity programs in lung cancer patients.

Perioperative exercise in lung cancer patients appears to be safe with improvement in operability, operative risk, post-operative complications, as well as increase exercise capacity.

«For about 80 percent of our patients with lung cancer, we don't have tests like [the one for] ALK to tell us what treatments will work best,» Shaw says.

«Lung cancer patients are usually treated with chemo, and they can do well, but you seldom see dramatic turnarounds,» Shaw says.

The difference with Xalkori is that a test exists to identify that slim percentage of lung cancer patients (about 8,000 people in the United States and 40,000 worldwide each year) who would respond well.

A new study shows that variations in the genes of Japanese and American lung cancer patients may contribute to how well their disease responds to chemotherapy

Susan Galbraith, head of the oncology innovative medicines unit at AstraZeneca, said: «Lung cancer is still the leading cancer killer, and we are working on a number of potential treatment options that could provide patients with a better chance of beating the disease.

The drugs are already approved for treatment of patients with advanced breast cancer as well as ovarian, pancreatic and certain lung cancers.

«It takes too long for patients who have suspected lung cancer to get final treatment, and too many patients skip vital steps needed to decide the best possible treatment,» said Dr. Osarogiagbon.

«Lung cancer care is complicated, and all key specialists must be actively engaged early on with each patient to determine the best sequence of tests and treatment for each individual,» said Dr. Osarogiagbon.

«More and more patients are being cured of lung cancer, with both surgery and radiation as good treatment options,» said lead author Nirav S. Kapadia, MD, of Dartmouth - Hitchcock Medical Center in New Hampshire.

Patients undergoing surgery for lung cancer may wait too long to receive treatment, and too many patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to an article in the August 2015 issue of The Annals of Thoracic Patients undergoing surgery for lung cancer may wait too long to receive treatment, and too many patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to an article in the August 2015 issue of The Annals of Thoracic patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to an article in the August 2015 issue of The Annals of Thoracic Surgery.

This better understanding of BCX's molecular mechanism could lead to dietary recommendations for patients undergoing chemotherapy for lung cancer and for those who have survived, said Wang, who is also a professor at the Friedman School.

They suggested that the melanoma and lung cancer patients had done best because those cancers have lots of mutations, a consequence of exposure to sunlight and cigarette smoke.

Why: Staging lung cancer correctly ensures the best care for patients.

The drug is given to a subset of lung cancer patients at a daily dose of 150 mg, but whether this dosing strategy was the best way to prolong survival had not been empirically tested.

The work that garnered the honor, «An analysis of the risk and benefit of neoadjuvant chemotherapy among patients undergoing surgery for non-small cell lung cancer,» examined data from more than 134,000 patients in the National Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term surcancer,» examined data from more than 134,000 patients in the National Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term surCancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term survival.

While «ROS1 fusion» has primarily been studied in lung cancer, the Global ROS1 Initiative includes ROS1 - positive (ROS1 +) patients with melanoma and pancreatic cancer as well.

DNA Detectives Find Genetic Markers for Lung Cancers Most Likely to Recur Researchers at the Johns Hopkins Kimmel Cancer Center uncovered clearly recognizable genetic alterations in tumors and tissue removed from patients with early - stage lung cancers that look like good predictors of which of these cancers are more likely to reLung Cancers Most Likely to Recur Researchers at the Johns Hopkins Kimmel Cancer Center uncovered clearly recognizable genetic alterations in tumors and tissue removed from patients with early - stage lung cancers that look like good predictors of which of these cancers are more likely toCancers Most Likely to Recur Researchers at the Johns Hopkins Kimmel Cancer Center uncovered clearly recognizable genetic alterations in tumors and tissue removed from patients with early - stage lung cancers that look like good predictors of which of these cancers are more likely to relung cancers that look like good predictors of which of these cancers are more likely tocancers that look like good predictors of which of these cancers are more likely tocancers are more likely to recur.

These results should support the idea that IMRT is the radiation therapy of choice for lung cancer patients as well.

Clinical trial showed Merck's immune boosting drug Keytruda is better than chemotherapy in patients with lung cancer.